Organisation › Details

Telix Pharmaceuticals Ltd. (ASX: TLX)

Telix Pharmaceuticals Limited (Telix Group, Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). *

 

Period Start 2017-04-12 existent
Products Industry RADIOPHARMACEUTICAL
  Industry 2 biopharmaceutical
Person Person Behrenbruch, Christian (Telix 201511– CEO before ImaginAb CEO + Co-Founder)
     
Region Region Melbourne VIC
  Country Australia
  Street 55 Flemington Road
  City 3051 Melbourne VIC
    Address record changed: 2018-07-09
     
Basic data Employees n. a.
     
    * Document for �About Section�: Abzena plc. (7/2/18). "Press Release: Abzena and Telix Sign Strategic Manufacturing and Bioconjugation Agreement". Cambridge & Melbourne.
     
   
Record changed: 2018-09-12

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for Telix Pharmaceuticals Ltd. (ASX: TLX)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] – Putting Information into Context 600x60px




» top